B-cell restriction – an alternative piece to the puzzle

References

• Wilson CB, Marcuse EK. Vaccine safety–vaccine benefits: science and the public‘s perception. Nat Rev Immunol. 2001;1(2):160–65. doi:10.1038/35100585.
   PubMed Web of Science ®Google Scholar
• Meissner HC, Strebel PM, Orenstein WA. Measles vaccines and the potential for worldwide eradication of measles. Pediatrics. 2004;114(4):1065–69. doi:10.1542/peds.2004-0440.
   PubMed Web of Science ®Google Scholar
• Barquet N, Domingo P. Smallpox: the triumph over the most terrible of the ministers of death. Ann Intern Med. 1997;127:635–42.
   PubMed Web of Science ®Google Scholar
• Henderson DA. The history of smallpox eradication. Henry E Sigerist Suppl Bull Hist Med. 1980;4:99–114.
   PubMedGoogle Scholar
• Henderson DA. Smallpox eradication. Public Health Rep. 1980;95:422–26.
   PubMed Web of Science ®Google Scholar
• Hozumi N, Tonegawa S. Evidence for somatic rearrangement of immunoglobulin genes coding for variable and constant regions. Proc Natl Acad Sci U S A. 1976;73:3628–32.
   PubMed Web of Science ®Google Scholar
• Marc MA, Dominguez-Alvarez E, Gamazo C. Nucleic acid vaccination strategies against infectious diseases. Expert Opin Drug Deliv. 2015;12(12):1851–65. doi:10.1517/17425247.2015.1077559.
   PubMed Web of Science ®Google Scholar
• Robinson HL. Nucleic acid vaccines: an overview. Vaccine. 1997;15:785–87.
   PubMed Web of Science ®Google Scholar
• Knirel YA. Polysaccharide antigens of Pseudomonas aeruginosa. Crit Rev Microbiol. 1990;17(4):273–304. doi:10.3109/10408419009105729.
   PubMed Web of Science ®Google Scholar
• Liu CC, Ye XS. Carbohydrate-based cancer vaccines: target cancer with sugar bullets. Glycoconj J. 2012;29(5–6):259–71. doi:10.1007/s10719-012-9399-9.
   PubMed Web of Science ®Google Scholar
• Larrouy-Maumus G, Layre E, Clark S, Prandi J, Rayner E, Lepore M, de Libero G, Williams A, Puzo G, Gilleron M. Protective efficacy of a lipid antigen vaccine in a guinea pig model of tuberculosis. Vaccine. 2017;35(10):1395–402. doi:10.1016/j.vaccine.2017.01.079.
   PubMed Web of Science ®Google Scholar
• Leitner DR, Feichter S, Schild-Prufert K, Rechberger GN, Reidl J, Schild S. Lipopolysaccharide modifications of a cholera vaccine candidate based on outer membrane vesicles reduce endotoxicity and reveal the major protective antigen. Infect Immun. 2013;81(7):2379–93. doi:10.1128/IAI.01382-12.
   PubMed Web of Science ®Google Scholar
• Vartabedian VF, Savage PB, Teyton L. The processing and presentation of lipids and glycolipids to the immune system. Immunol Rev. 2016;272(1):109–19. doi:10.1111/imr.12431.
   PubMed Web of Science ®Google Scholar
• Gitlin AD, Shulman Z, Nussenzweig MC. Clonal selection in the germinal centre by regulated proliferation and hypermutation. Nature. 2014;509(7502):637–40. doi:10.1038/nature13300.
   PubMed Web of Science ®Google Scholar
• Eisen HN, Siskind GW. Variations in affinities of antibodies during the immune response. Biochemistry. 1964;3:996–1008.
   PubMed Web of Science ®Google Scholar
• Milstein C. From antibody structure to immunological diversification of immune response. Science. 1986;231:1261–68.
   PubMed Web of Science ®Google Scholar
• Milstein C. Affinity maturation of antibodies. Immunol Today. 1991;12(2):93–94. doi:10.1016/0167-5699(91)90164-O.
   PubMedGoogle Scholar
• Poulsen TR, Jensen A, Haurum JS, Andersen PS. Limits for antibody affinity maturation and repertoire diversification in hypervaccinated humans. J Immunol. 2011;187(8):4229–35. doi:10.4049/jimmunol.1000928.
   PubMed Web of Science ®Google Scholar
• Amorij JP, Huckriede A, Wilschut J, Frijlink HW, Hinrichs WL. Development of stable influenza vaccine powder formulations: challenges and possibilities. Pharm Res. 2008;25(6):1256–73. doi:10.1007/s11095-008-9559-6.
   PubMed Web of Science ®Google Scholar
• Kumar A, Meldgaard TS, Bertholet S. Novel platforms for the development of a universal influenza vaccine. Front Immunol. 2018;9:600. doi:10.3389/fimmu.2018.00600.
   PubMed Web of Science ®Google Scholar
• Medina-Ramirez M, Sanders RW, Sattentau QJ. Stabilized HIV-1 envelope glycoprotein trimers for vaccine use. Curr Opin HIV AIDS. 2017;12(3):241–49. doi:10.1097/COH.0000000000000363.
   PubMed Web of Science ®Google Scholar
• Rios A. Fundamental challenges to the development of a preventive HIV vaccine. Curr Opin Virol. 2018;29:26–32. doi:10.1016/j.coviro.2018.02.004.
   PubMed Web of Science ®Google Scholar
• Coughlin MM, Prabhakar BS. Neutralizing human monoclonal antibodies to severe acute respiratory syndrome coronavirus: target, mechanism of action, and therapeutic potential. Rev Med Virol. 2012;22(1):2–17. doi:10.1002/rmv.706.
   PubMed Web of Science ®Google Scholar
• Prabakaran P, Gan J, Feng Y, Zhu Z, Choudhry V, Xiao X, Ji X, Dimitrov DS. Structure of severe acute respiratory syndrome coronavirus receptor-binding domain complexed with neutralizing antibody. J Biol Chem. 2006;281(23):15829–36. doi:10.1074/jbc.M600697200.
   PubMed Web of Science ®Google Scholar
• Sui J, Li W, Murakami A, Tamin A, Matthews LJ, Wong SK, Moore MJ, Tallarico AS, Olurinde M, Choe H, et al. Potent neutralization of severe acute respiratory syndrome (SARS) coronavirus by a human mAb to S1 protein that blocks receptor association. Proc Natl Acad Sci U S A. 2004;101:2536–41.
   PubMed Web of Science ®Google Scholar
• Knossow M, Skehel JJ. Variation and infectivity neutralization in influenza. Immunology. 2006;119(1):1–7. doi:10.1111/j.1365-2567.2006.02421.x.
   PubMed Web of Science ®Google Scholar
• Kwong PD, Wyatt R, Robinson J, Sweet RW, Sodroski J, Hendrickson WA. Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody. Nature. 1998;393(6686):648–59. doi:10.1038/31405.
   PubMed Web of Science ®Google Scholar
• Behrens AJ, Crispin M. Structural principles controlling HIV envelope glycosylation. Curr Opin Struct Biol. 2017;44:125–33. doi:10.1016/j.sbi.2017.03.008.
   PubMed Web of Science ®Google Scholar
• Goffard A, Callens N, Bartosch B, Wychowski C, Cosset FL, Montpellier C, Dubuisson J. Role of N-linked glycans in the functions of hepatitis C virus envelope glycoproteins. J Virol. 2005;79(13):8400–09. doi:10.1128/JVI.79.13.8400-8409.2005.
   PubMed Web of Science ®Google Scholar
• Tate MD, Job ER, Deng YM, Gunalan V, Maurer-Stroh S, Reading PC. Playing hide and seek: how glycosylation of the influenza virus hemagglutinin can modulate the immune response to infection. Viruses. 2014;6(3):1294–316. doi:10.3390/v6031294.
   PubMed Web of Science ®Google Scholar
• Vieyres G, Thomas X, Descamps V, Duverlie G, Patel AH, Dubuisson J. Characterization of the envelope glycoproteins associated with infectious hepatitis C virus. J Virol. 2010;84(19):10159–68. doi:10.1128/JVI.01180-10.
   PubMed Web of Science ®Google Scholar
• Mayr LM, Su B, Moog C. Non-neutralizing antibodies directed against HIV and their functions. Front Immunol. 2017;8:1590. doi:10.3389/fimmu.2017.01590.
   PubMed Web of Science ®Google Scholar
• Douek DC, Kwong PD, Nabel GJ. The rational design of an AIDS vaccine. Cell. 2006;124(4):677–81. doi:10.1016/j.cell.2006.02.005.
   PubMed Web of Science ®Google Scholar
• Prabakaran P, Dimitrov AS, Fouts TR, Dimitrov DS. Structure and function of the HIV envelope glycoprotein as entry mediator, vaccine immunogen, and target for inhibitors. Adv Pharmacol. 2007;55:33–97. doi:10.1016/S1054-3589(07)55002-7.
   PubMedGoogle Scholar
• Ward AB, Wilson IA. The HIV-1 envelope glycoprotein structure: nailing down a moving target. Immunol Rev. 2017;275(1):21–32. doi:10.1111/imr.12507.
   PubMed Web of Science ®Google Scholar
• Moore JP, McKeating JA, Weiss RA, Sattentau QJ. Dissociation of gp120 from HIV-1 virions induced by soluble CD4. Science. 1990;250:1139–42.
   PubMed Web of Science ®Google Scholar
• Smyth RP, Davenport MP, Mak J. The origin of genetic diversity in HIV-1. Virus Res. 2012;169(2):415–29. doi:10.1016/j.virusres.2012.06.015.
   PubMed Web of Science ®Google Scholar
• Davidson S. Treating influenza infection, from now and into the future. Front Immunol. 2018;9:1946. doi:10.3389/fimmu.2018.01946.
   PubMed Web of Science ®Google Scholar
• Mascola JR, Montefiori DC. HIV-1: nature‘s master of disguise. Nat Med. 2003;9(4):393–94. doi:10.1038/nm0403-393.
   PubMed Web of Science ®Google Scholar
• Freund NT, Wang H, Scharf L, Nogueira L, Horwitz JA, Bar-On Y, Golijanin J, Sievers SA, Sok D, Cai H, et al. Coexistence of potent HIV-1 broadly neutralizing antibodies and antibody-sensitive viruses in a viremic controller. Sci Transl Med. 2017;9(373). doi:10.1126/scitranslmed.aal2144.
   PubMed Web of Science ®Google Scholar
• Liao HX, Lynch R, Zhou T, Gao F, Alam SM, Boyd SD, Fire AZ, Roskin KM, Schramm CA, Zhang Z, et al. Co-evolution of a broadly neutralizing HIV-1 antibody and founder virus. Nature. 2013;496(7446):469–76. doi:10.1038/nature12053.
   PubMed Web of Science ®Google Scholar
• Scheid JF, Mouquet H, Ueberheide B, Diskin R, Klein F, Oliveira TY, Pietzsch J, Fenyo D, Abadir A, Velinzon K, et al. Sequence and structural convergence of broad and potent HIV antibodies that mimic CD4 binding. Science. 2011;333(6049):1633–37. doi:10.1126/science.1207227.
   PubMed Web of Science ®Google Scholar
• Fera D, Schmidt AG, Haynes BF, Gao F, Liao HX, Kepler TB, Harrison SC. Affinity maturation in an HIV broadly neutralizing B-cell lineage through reorientation of variable domains. Proc Natl Acad Sci U S A. 2014;111(28):10275–80. doi:10.1073/pnas.1409954111.
   PubMed Web of Science ®Google Scholar
• Ingale J, Tran K, Kong L, Dey B, McKee K, Schief W, Kwong PD, Mascola JR, Wyatt RT. Hyperglycosylated stable core immunogens designed to present the CD4 binding site are preferentially recognized by broadly neutralizing antibodies. J Virol. 2014;88(24):14002–16. doi:10.1128/JVI.02614-14.
   PubMed Web of Science ®Google Scholar
• Kulp DW, Steichen JM, Pauthner M, Hu X, Schiffner T, Liguori A, Cottrell CA, Havenar-Daughton C, Ozorowski G, Georgeson E, et al. Structure-based design of native-like HIV-1 envelope trimers to silence non-neutralizing epitopes and eliminate CD4 binding. Nat Commun. 2017;8(1):1655. doi:10.1038/s41467-017-01549-6.
   PubMedGoogle Scholar
• de Taeye SW, de la Pena AT, Vecchione A, Scutigliani E, Sliepen K, Burger JA, van der Woude P, Schorcht A, Schermer EE, van Gils MJ, et al. Stabilization of the gp120 V3 loop through hydrophobic interactions reduces the immunodominant V3-directed non-neutralizing response to HIV-1 envelope trimers. J Biol Chem. 2018;293(5):1688–701. doi:10.1074/jbc.RA117.000709.
   PubMed Web of Science ®Google Scholar
• de Taeye SW, Ozorowski G, de la Pena AT, Guttman M, Julien JP, van Den Kerkhof TL, Burger JA, Pritchard LK, Pugach P, Yasmeen A, et al. Immunogenicity of stabilized HIV-1 envelope trimers with reduced exposure of non-neutralizing epitopes. Cell. 2015;163(7):1702–15. doi:10.1016/j.cell.2015.11.056.
   PubMed Web of Science ®Google Scholar
• Sanders RW, Derking R, Cupo A, Julien JP, Yasmeen A, de Val N, Kim HJ, Blattner C, de la Pena AT, Korzun J, et al. A next-generation cleaved, soluble HIV-1 Env trimer, BG505 SOSIP.664 gp140, expresses multiple epitopes for broadly neutralizing but not non-neutralizing antibodies. PLoS Pathog. 2013;9(9):e1003618. doi:10.1371/journal.ppat.1003618.
   PubMed Web of Science ®Google Scholar
• Mattoo S, Cherry JD. Molecular pathogenesis, epidemiology, and clinical manifestations of respiratory infections due to Bordetella pertussis and other Bordetella subspecies. Clin Microbiol Rev. 2005;18(2):326–82. doi:10.1128/CMR.18.2.326-382.2005.
   PubMed Web of Science ®Google Scholar
• Pinto MV, Merkel TJ. Pertussis disease and transmission and host responses: insights from the baboon model of pertussis. J Infect. 2017;74(Suppl 1):S114–S119. doi:10.1016/S0163-4453(17)30201-3.
   PubMedGoogle Scholar
• Maupas P, Goudeau A, Coursaget P, Drucker J, Bagros P. Immunisation against hepatitis B in man. Lancet. 1976;1:1367–70.
   PubMed Web of Science ®Google Scholar
• Pasek M, Goto T, Gilbert W, Zink B, Schaller H, MacKay P, Leadbetter G, Murray K. Hepatitis B virus genes and their expression in E. coli. Nature. 1979;282:575–79.
   PubMed Web of Science ®Google Scholar
• Szmuness W, Stevens CE, Harley EJ, Zang EA, Oleszko WR, William DC, Sadovsky R, Morrison JM, Kellner A. Hepatitis B vaccine: demonstration of efficacy in a controlled clinical trial in a high-risk population in the United States. N Engl J Med. 1980;303(15):833–41. doi:10.1056/NEJM198010093031501.
   PubMed Web of Science ®Google Scholar
• Centers for Disease, C. and Prevention. FDA licensure of bivalent human papillomavirus vaccine (HPV2, Cervarix) for use in females and updated HPV vaccination recommendations from the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep. 2010;59(20):626–29.
   PubMedGoogle Scholar
• Harper DM. Currently approved prophylactic HPV vaccines. Expert Rev Vaccines. 2009;8(12):1663–79. doi:10.1586/erv.09.123.
   PubMed Web of Science ®Google Scholar
• Petrosky E, Bocchini JA Jr., Hariri S, Chesson H, Curtis CR, Saraiya M, Unger ER, Markowitz LE. Centers for disease, and prevention, use of 9-valent human papillomavirus (HPV) vaccine: updated HPV vaccination recommendations of the advisory committee on immunization practices. MMWR Morb Mortal Wkly Rep. 2015;64:300–04.
   PubMed Web of Science ®Google Scholar
• Villa LL, Costa RL, Petta CA, Andrade RP, Ault KA, Giuliano AR, Wheeler CM, Koutsky LA, Malm C, Lehtinen M, et al. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol. 2005;6(5):271–78. doi:10.1016/S1470-2045(05)70101-7.
   PubMed Web of Science ®Google Scholar
• Gershoni JM, Roitburd-Berman A, Siman-Tov DD, Tarnovitski Freund N, Weiss Y. Epitope mapping: the first step in developing epitope-based vaccines. BioDrugs. 2007;21(3):145–56. doi:10.2165/00063030-200721030-00002.
   PubMed Web of Science ®Google Scholar
• Rubinstein ND, Mayrose I, Halperin D, Yekutieli D, Gershoni JM, Pupko T. Computational characterization of B-cell epitopes. Mol Immunol. 2008;45(12):3477–89. doi:10.1016/j.molimm.2007.10.016.
   PubMed Web of Science ®Google Scholar
• Freund NT, Roitburd-Berman A, Sui J, Marasco WA, Gershoni JM. Reconstitution of the receptor-binding motif of the SARS coronavirus. Protein Eng Des Sel. 2015;28(12):567–75. doi:10.1093/protein/gzv052.
   PubMed Web of Science ®Google Scholar
• Li F, Li W, Farzan M, Harrison SC. Structure of SARS coronavirus spike receptor-binding domain complexed with receptor. Science. 2005;309(5742):1864–68. doi:10.1126/science.1116480.
   PubMed Web of Science ®Google Scholar
• Flipse J, Wilschut J, Smit JM. Molecular mechanisms involved in antibody-dependent enhancement of dengue virus infection in humans. Traffic. 2013;14(1):25–35. doi:10.1111/tra.12012.
   PubMed Web of Science ®Google Scholar
• Kliks SC, Nisalak A, Brandt WE, Wahl L, Burke DS. Antibody-dependent enhancement of dengue virus growth in human monocytes as a risk factor for dengue hemorrhagic fever. Am J Trop Med Hyg. 1989;40:444–51.
   PubMed Web of Science ®Google Scholar
• Johansson BE, Brett IC. Changing perspective on immunization against influenza. Vaccine. 2007;25(16):3062–65. doi:10.1016/j.vaccine.2007.01.030.
   PubMed Web of Science ®Google Scholar
• Richman DD, Wrin T, Little SJ, Petropoulos CJ. Rapid evolution of the neutralizing antibody response to HIV type 1 infection. Proc Natl Acad Sci U S A. 2003;100(7):4144–49. doi:10.1073/pnas.0630530100.
   PubMed Web of Science ®Google Scholar
• Bar KJ, Tsao CY, Iyer SS, Decker JM, Yang Y, Bonsignori M, Chen X, Hwang KK, Montefiori DC, Liao HX, et al. Early low-titer neutralizing antibodies impede HIV-1 replication and select for virus escape. PLoS Pathog. 2012;8(5):e1002721. doi:10.1371/journal.ppat.1002721.
   PubMed Web of Science ®Google Scholar
• Duan H, Struble E, Zhong L, Mihalik K, Major M, Zhang P, Feinstone S, Feigelstock D. Hepatitis C virus with a naturally occurring single amino-acid substitution in the E2 envelope protein escapes neutralization by naturally-induced and vaccine-induced antibodies. Vaccine. 2010;28(25):4138–44. doi:10.1016/j.vaccine.2010.04.024.
   PubMed Web of Science ®Google Scholar
• Wei X, Decker JM, Wang S, Hui H, Kappes JC, Wu X, Salazar-Gonzalez JF, Salazar MG, Kilby JM, Saag MS, et al. Antibody neutralization and escape by HIV-1. Nature. 2003;422(6929):307–12. doi:10.1038/nature01470.
   PubMed Web of Science ®Google Scholar